A Study On The Relationship Between The ERCC1 Gene Polymorphisms And The Effect Of Cisplatin Treating Advanced Esophageal Cancer

Objective:Many studies show that the ERCC1(excision repair cross-complementation group 1) gene polymorphisms are associated with the effect of platinum-based treatment on non-small-cell lung cancer,colorectal cancer and ovarian cancer,and they could be predictive factors.Therefore,in this study,we detected the ERCC1 gene polymorphisms of the advcanced esophageal cancer patients treated with cisplatin-based chemotherapies,analyzed whether the polymorphisms and other clincal and pathological factors were related to tumor remission and PFS(progression free survival).Methods:117 advanced esophageal cancer patients were enrolled between September 2006 and September 2008 in Anhui provincial hospital and Anhui oncology hospital. They were all treated with cisplatin combined with fluorouracil chemotherapies.The tumor responses and PFS were assessd.The polymorphisms were detected after DNA PCR amplifications,which extracted from peripheral blood karyocytes before the first chemotherapies used.In the end,of 98 patients completed the trials and the data were available.Statistical anaysis was performed using SPSS statistical software package 13.0 with P≤0.05 considered as statistically signficant.Univariate ananysis by chi-square test and multivarariate analysis by logistic regression model were used for remission rate.PFS curves were calculated accading to Kaplan-Meier method.Univariate ananysis by log-rank test and multivarariate analysis by Cox regression model were used for PFS.Results:In these 98 patients,there were 80 male and 18 female;76 patients were no yunger than 60 years,23 patients were yunger than 60 years;the pathological types of all were squamous cell carcinoma,and of 20 were poor differentiated,44 were moderately differentiated,34 were well differentiated;there were17 patients'KPS as 70,80 patients'KPS as 80 and 44 patients'KPS as 90;there were 23 patients with liver metastasis and 75 patients without liver metastasis;there were 16,37 and 45 patients' ERCC1-C8092A genetype as A/A,A/C and C/C respectively;there were 7,26 and 65 patients' ERCC1-C19007T genetype as T/T,C/T and C/C respectively.On univariate analysis,ERCC1 C8092 and C19007 gene polymorphisms,liver metastasis and tumor differentiation level related to remission rates;ERCC1 C8092 and C19007 gene polymorphisms,liver metastasis,tumor differentiation level and performance status were related to PFS.However,On multivariate analysis,neither remission rate or PFS was correlated with liver metastasis.Concolutions:Advanced esophageal cancer patient with ERCC1-C8092A genotypes asA/A or A/C,ERCC1-C19007T genotype as C/C or well or moderately differentiated tumor cells may get more benefit in cisiplatin-based chemothetrapy.The patients could get more benefit for beter performance status.